IPP Bureau
Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron
By IPP Bureau - November 26, 2021
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Baidu and Sanofi to collaborate for next-gen mRNA therapy and vaccines
By IPP Bureau - November 26, 2021
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Aadi Bioscience secures U.S FDA approval of its first product Fyarro
By IPP Bureau - November 26, 2021
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Sanofi invests US $ 180 mn in Owkin’s AI for oncology pipeline
By IPP Bureau - November 26, 2021
Owkin builds best-in-class predictive biomedical AI models and robust data sets
Indian Pharmaceutical Market reports slower growth in October
By IPP Bureau - November 26, 2021
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
NFHS-5 shows momentum towards achieving SDG
By IPP Bureau - November 25, 2021
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
GreenLight Biosciences and Samsung Biologics to build vaccine capacity
By IPP Bureau - November 25, 2021
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Sputnik Light in India by December: RDIF
By IPP Bureau - November 25, 2021
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
By IPP Bureau - November 25, 2021
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
ICMR approves Meril’s Rapid Antigen Test kit
By IPP Bureau - November 25, 2021
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
Bharat Biotech updates on the Lancet study on Covaxin efficacy
By IPP Bureau - November 25, 2021
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
.jpg "Air pollution reduces life expectancy by eight years in India")
Air pollution reduces life expectancy by eight years in India
By IPP Bureau - November 25, 2021
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Gastrointestinal disorders increasing in India
By IPP Bureau - November 25, 2021
It is estimated that one-third of our country’s population has some form of these disorders
Boehringer Ingelheim India enters Guinness World Records through its Stroke campaign
By IPP Bureau - November 25, 2021
The week-long campaign received a record 17.691 pledges
ADB approves US $ 1.5 bn for Covid-19 vaccines in India
By IPP Bureau - November 25, 2021
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
